P
rimary tumors can affect organ functions, either mechanically when they grow to a considerable size or via production of hormones. However, mortality of cancer patients is in most cases due to formation of secondary growths.
1,2
Consequently, various drugs are currently employed in clinical trials to impair specific steps of cancer metastasis such as mesenchymal or amoeboid cell migration, intravasation and/or colonization. 2 From the clinical point of view, targeting late metastatic processes such as extravasation or colonization might be required for cancer patients that bear already dormant micrometastases in their capillaries which have left behind earlier metastatic steps. Development of such drugs needs characterization of molecular targets implicated in distinct steps of cancer metastasis.
Extravasation of tumor cells resembles diapedesis of leukocytes which penetrate blood vessel walls at sites of inflammation. Similar to leukocytes, tumor cells attach to endothelial cells through adhesion molecules such as selectins. 2 More ingenious, instead of inventing extravasation a new, tumor cells can attract neutrophils via chemotactic factors and use them as carriage horses to leave the capillaries. 3 A related role has been attributed to platelets that are exploited by tumor cells for attachment to blood vessel endothelia. Attachment is mediated by a fibrinogen coat that can shield tumor cells from shear stress or lytic NK cell attack. Although platelets do not guide tumor cells through the blood vessel wall, they secrete factors such as TGFb1 that promote epithelial to mesenchymal transition and extravasation. 4 Additional support for extravasation
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Institute for Cancer Research (ICR) & Comprehensive Cancer Center (CCC); Medical University of Vienna; Vienna, Austria is provided by vascular permeability factors such as vascular endothelial growth factor (VEGF). The founding member of the VEGF family, VEGF-A, was initially also termed "vascular permeability factor" (VPF) based on its ability to enhance the leakiness of blood vessels to plasma and plasma proteins. VEGF is produced by stromal cells but many cancer cells (including cells of hematologic malignancies) have acquired the ability to contribute to VEGF production. 5 Thus, VEGF does not only promote angiogenesis and vascular permeability in primary tumors but also extravasation of disseminated micrometastases. 6 Alternative factors that modulate endothelial barrier integrity are extracellular matrix proteins such as TGFb-induced (TGFBI) 7 or the protease thrombin 8 that act on endothelial cells and result in cytoskeletal rearrangements (Fig. 1) .
In a recent issue of Cancer Cell, Wolf and coworkers have reported about a novel mechanism in tumor cell metastasis that involves the chemokine CCL2. 9 This mechanism goes beyond the well-characterized pro-metastatic functions of CCL2/ CCR2-signaling in primary tumors 10 and provides already disseminated cancer cells with an enhanced potential for extravasation and colonization. Chemokines are mediators of heterotypic interactions between tumor cells and their microenvironment. These interactions are essential for acquisition of invasive and metastatic behaviors. Chemokines bind to extracellular matrix compounds such as heparin and proteoglycans. They activate signaling in target cells via 7-span transmembrane chemokine receptors and trimeric G proteins. The activity of chemokines in metastasis is pleiotropic: they are implicated in of CCR2 + Ly6C high monocytes (which might be used by tumor cells as carriers through the vessel wall) and (2) enhancement of local vascular permeability. Of note, the permeabilizing effect of CCL2 on the endothelial compartment in this metastasis model turned out to be more important for extravasation than chemoattraction of leukocytes. CCL2 exerted this permeabilizing effect in a transient and non-systemic manner. Vascular endothelia became impermeable again after tumor cells have found their way through the vessel walls and established secondary growths in metastatic niches. The relevant CCL2/CCR2 downstream signaling pathways for extravasation were identified in vitro using tumor cell transmigration in the presence and absence of specific inhibitors. These experiments, together with additional experiments performed in mice, revealed the JAK2/STAT5 and p38MAPK pathways downstream of CCL2/CCR2 as crucial for induction of vascular permeability. p38MAPK is known to promote CCL2-producing tumor cells. They used lung colonization by MC38 colorectal cancer cells in mice as model for identification of molecular events triggered by CCL2/ CCR2 during tumor cell extravasation. The C57BL/6-syngeneic MC38 colonization model is not suitable for investigation of initial events of cancer metastasis such as local invasiveness or intravasation. However, it offers the advantage to appropriately manipulate gene expression in transplanted cancer cells, a task that is more difficult to achieve in primary tumor models. CCR2 functions were selectively ablated, either in metastatic target tissues (by using CCR2-deficient recipient mice) or in tumor cells (by shRNA-mediated knock-down of CCR2). Moreover, reciprocal bone marrow reconstitution experiments were performed to evaluate the implication of monocytic CCL2/CCRsignaling in tumor cell extravasation. These experiments demonstrated that tumor cellderived CCL2 promotes extravasation by a dual mechanism: (1) chemoattraction many metastatic steps such as local invasiveness, intravasation, anoikis, extravasation, chemotaxis and colonization. 10 The chemokine CCL2 (also termed monocyte chemotactic protein 1 or MCP-1) is implicated in immunosuppression and tumor angiogenesis. 4, 11 Moreover, CCL2 represents a major chemotactic factor for attraction of myeloid-derived suppressor cells (MDSCs), circulating monocytes and other immune cells to the tumor stroma.
11,12 Consequently, CCL2 receptors CCR2 and CCR4 are expressed on immune cells (monocytes, macrophages, dendritic cells, NK cells and T cells). CCR2 is also expressed on epithelial and endothelial cells whereas CCR4 is not. Apart from the well characterized prometastatic activities in tumors (e.g., activation in endothelial cells promotes tumor neovascularization via matrix metalloproteinase MMP-14 activity 13 ), Wolf and coworkers discovered a distinct function of CCL2/CCR2-signaling in distant endothelia of capillaries that is triggered by 23 Activation of the thrombin receptor pAr-1 on endothelial cells leads to g proteinmediated activation of rhoA and rhoA downstream signaling components that converge on the increase of actomyosin contractility and cell-cell junction remodeling. Adapted from reference 8. (B) VegF, derived from tumor cells at the site of metastasis, activates focal adhesion kinase (FAK) in endothelial cells that subsequently binds to the cytoplasmic tail of Ve-cadherin (Ve-cad). At this location, β-catenin (β-cat) is phosphorylated by FAK and dissociates from Ve-cadherin leading to endothelial cell junctional breakdown. 6 Additional modes how VegF affects vascular permeability have also been described. 24 (C) plateletes can support metastasis in several ways: platelet-derived TgFb1 activates SMADs in tumor cells. Simultaneously, nFκB is activated by platelet-tumor cell contacts. Both synergize to induce epithelial-mesenchymal transition (eMT) thereby promoting extravasation. Adapted from reference 4. (D) human melanoma cells readily extravasate when co-injected with human neutrophils into recipient mice. This effect is mediated by melanoma-derived iL-8 which attracts neutrophils and induces expression of β2-integrin (β2-int). neutrophils anchor tumors cells to endothelial cells via contacts of β2-integrin to extracellular matrix compounds and the cell adhesion molecule icAM-1.
3 (E) Tumor cell-derived ccL2 can activate corresponding ccr2 receptors on endothelial cells thereby inducing JAK2/STAT5 and p38MApK signaling pathways. Both pathways synergize to increase vascular permeability. p38MApK induces expression of e-Selectin (e-Sel) in endothelial cells which promotes attachment of tumor cells. Simultaneously, monocytes are attracted by ccL2 which support extravasation of tumor cells through walls of capillaries with reduced barrier function. Adapted from reference 9.
11. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen and coworkers support continuation of therapeutic approaches to block CCL2/ CCR2-signaling. Moreover, they suggest new approaches that target JAK2/ STAT5 and p38MAPK in the endothelial compartment at micrometastatic sites. Additional studies are needed to clarify if CCL2/CCR2-signaling is generally used by cancer cells for extravasation or if other chemokine/chemokine receptor pairs have similar pro-metastatic activities at distant sites. These studies might provide novel biomarkers for metastasis and increase the number of potential molecular targets for anti-metastatic therapies.
